Physician
Northwest Pathology PLLC
Northwest Pathology PLLC was paid $17.79M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 67% of everything it billed.
33Billing provider infoNORTHWEST PATHOLOGY PLLC
BELLINGHAM, WA 98225
BELLINGHAM, WA 98225
33aNPI1235193590assigned 04/13/2006
33bProvider typeNeuropathology Physician
28Total paid$17.79M
24GClaims513,883
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,794 | $753K | |
| 2019 | 23,914 | $747K | |
| 2020 | 77,996 | $4.91M | |
| 2021 | 213,770 | $6.77M | |
| 2022 | 111,894 | $3.22M | |
| 2023 | 48,005 | $866K | |
| 2024incomplete | 16,510 | $537K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 67% | 167,671 | 136,036 | $11.90M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 11% | 51,862 | 49,584 | $1.96M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.9% | 41,722 | 35,218 | $880K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.9% | 16,441 | 16,025 | $509K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.8% | 19,494 | 19,069 | $506K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.1% | 11,985 | 11,657 | $368K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 11,955 | 11,627 | $366K |
| 87481 | <1% | 4,303 | 2,616 | $178K | |
| 88307 | <1% | 2,800 | 2,702 | $151K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,056 | 3,910 | $116K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,867 | 1,642 | $108K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,717 | 1,407 | $66K |
71 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 690 | $54K |
| 88304 | <1% | 5,714 | $51K | |
| 88342 | <1% | 2,630 | $49K | |
| 87511 | <1% | 1,629 | $46K | |
| 88142 | <1% | 2,187 | $41K | |
| 87634 | <1% | 744 | $41K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,419 | $30K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 69 | $28K |
| 88141 | <1% | 1,815 | $28K | |
| 88312 | <1% | 730 | $25K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,201 | $25K |
| 80061 | Lipid panel | <1% | 3,380 | $24K |
| 87529 | <1% | 443 | $23K | |
| 88341 | <1% | 926 | $23K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,060 | $22K |
| 87625 | <1% | 703 | $21K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,553 | $21K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 103,661 | $19K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,091 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,310 | $14K |
| 82607 | <1% | 1,494 | $12K | |
| 82746 | <1% | 1,144 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 377 | $8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 144 | $5K |
| 82728 | <1% | 583 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,047 | $4K |
| 86803 | <1% | 200 | $3K | |
| 87581 | <1% | 69 | $2K | |
| 83550 | <1% | 554 | $2K | |
| 85027 | <1% | 873 | $2K | |
| 87486 | <1% | 69 | $2K | |
| 83721 | <1% | 575 | $2K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 8,539 | $2K |
| 83540 | <1% | 600 | $2K | |
| 88108 | <1% | 238 | $2K | |
| 86769 | <1% | 42 | $2K | |
| 88360 | <1% | 88 | $2K | |
| 84436 | <1% | 437 | $2K | |
| 87340 | <1% | 147 | $1K | |
| 84479 | <1% | 392 | $1K | |
| 84439 | <1% | 232 | $1K | |
| 83970 | <1% | 57 | $1K | |
| 85610 | <1% | 359 | $1K | |
| 87070 | <1% | 132 | $824.15 | |
| 88302 | <1% | 149 | $731.52 | |
| 84481 | <1% | 45 | $713.89 | |
| 83735 | <1% | 163 | $623.89 | |
| 87653 | <1% | 44 | $603.04 | |
| 83880 | <1% | 55 | $589.91 | |
| 88189 | <1% | 13 | $560.34 | |
| 85046 | <1% | 188 | $467.57 | |
| 88112 | <1% | 53 | $460.69 | |
| 80076 | <1% | 42 | $212.93 | |
| 86702 | <1% | 15 | $188.30 | |
| 87563 | <1% | 20 | $171.09 | |
| 84100 | <1% | 52 | $158.19 | |
| 87186 | <1% | 35 | $135.71 | |
| 86701 | <1% | 15 | $123.76 | |
| 87077 | <1% | 28 | $120.48 | |
| 86140 | <1% | 28 | $103.07 | |
| 86706 | <1% | 13 | $88.57 | |
| 87088 | <1% | 50 | $84.81 | |
| 82977 | <1% | 16 | $65.25 | |
| 87205 | <1% | 15 | $63.75 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 206 | $50.73 |
| 85652 | <1% | 19 | $49.17 | |
| 99072 | <1% | 2,138 | $45.06 | |
| 81001 | <1% | 16 | $44.24 | |
| 85007 | <1% | 18 | $35.08 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 43 | $18.17 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 184 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLGAMOT, GREGORY (MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Mattison Pathology, L.L.P. | Dallas, TX | $9.71M |
| Mattison Pathology, L.L.P. | Lubbock, TX | $558K |
| Northwest Pathology PLLC | Bellingham, WA | $77K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.